Literature DB >> 6645784

Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rats.

J A Nielsen, D S Chapin, K E Moore.   

Abstract

The in vivo effects of four psychomotor stimulants (d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate) were determined on: 1) the rate of dopamine (DA) synthesis, as measured by the accumulation of dihydroxyphenylalanine (DOPA) after aromatic L-amino acid decarboxylase inhibition, in the striatum (terminals of nigrostriatal neurons) and in the nucleus accumbens and olfactory tubercle (terminals of mesolimbic neurons) and 2) the efflux of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) into cerebroventricular perfusates of conscious, freely-moving rats. d-Amphetamine and beta-phenylethylamine produced biphasic responses with lower doses of each drug increasing both the efflux of DOPAC and the rate of DA synthesis in the striatum. Higher doses of each drug either had no effect or actually decreased the efflux of DOPAC and also decreased the rate of DA synthesis in the striatum. On the other hand, cocaine and methylphenidate only decreased the efflux of DOPAC and the rate of DA synthesis in the striatum. The effects of the drugs on the rate of DA synthesis in the nucleus accumbens and olfactory tubercle were similar to, but less pronounced than those seen in the striatum. These results are consistent with the following suggestions: 1) low doses of d-amphetamine and beta-phenylethylamine facilitate the neuronal release of DA while higher doses of both drugs facilitate release and inhibit neuronal reuptake of the amine, and 2) cocaine and methylphenidate preferentially block the neuronal reuptake of DA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6645784     DOI: 10.1016/0024-3205(83)90674-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

2.  Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat.

Authors:  T Kuroki; T Tsutsumi; M Hirano; T Matsumoto; Y Tatebayashi; K Nishiyama; H Uchimura; A Shiraishi; T Nakahara; K Nakamura
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists.

Authors:  Michelle G Baladi; Lynette C Daws; Charles P France
Journal:  Neuropharmacology       Date:  2012-02-23       Impact factor: 5.250

4.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors:  G B Baker; R T Coutts; T S Rao
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

6.  Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites.

Authors:  T Aoyama; H Kotaki; Y Sawada; T Iga
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

7.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 8.  Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.

Authors:  Michael Huss; Wai Chen; Andrea G Ludolph
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.